Insect sting allergy and venom immunotherapy

Area of Science:

• Allergy and Immunology
• Immunotherapy Research
• Clinical Allergy

Background:

• Venom immunotherapy (VIT) is a crucial treatment for insect sting allergies.
• Understanding VIT's efficacy and safety is vital for patient management.
• Allergen immunotherapy (AIT) provides a general framework for evaluating VIT.

Purpose of the Study:

• To review specific aspects of venom immunotherapy (VIT).
• To contextualize VIT within the broader field of allergen immunotherapy (AIT).
• To inform clinical decision-making regarding VIT for insect sting allergies.

Main Methods:

• Discussions during the Immunotherapy Collegium II at the 2005 ACAAI Annual Meeting.
• Review of existing literature and clinical practices concerning VIT.
• Analysis of diagnostic criteria and treatment protocols for VIT.

Main Results:

• VIT recommendation requires detailed history, diagnostic tests, and understanding of disease natural history.
• Skin tests and radioallergosorbent tests are complementary diagnostic tools.
• Rush regimens for VIT are as safe as slower protocols; large local reactions are expected and do not limit maintenance dose.
• VIT achieves 85% immune tolerance after 5 years, compared to 30-50% for inhalant AIT.
• Children receiving 3-5 years of VIT experience lasting immune tolerance for 10-20 years.
• A persistent 10-15% risk of reaction exists post-treatment, influenced by prior reaction severity and treatment duration.

Conclusions:

• Appropriate VIT use necessitates understanding insect sting allergy's natural history.
• Further research into the mechanisms of successful immunotherapy is needed for optimal induction of immune tolerance.
• VIT is a highly effective treatment for preventing severe reactions to insect stings.